Takeda parts ways with Wave Life Sciences even with Huntington’s trial win
Takeda will not move forward with Wave Life Sciences on a Huntington’s disease drug, ending their collaboration that first started in 2018 with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
